Business Context and Reporting Period
Company: Prima BioMed Ltd (Note: Input metadata referenced "IMMUTEP Ltd," but the filing text identifies the registrant as Prima BioMed Ltd).
Reporting Period: Fiscal year ended June 30, 2012.
Business Overview: Prima BioMed is an Australian biotechnology company focused on developing personalized bio-therapeutics, primarily the autologous dendritic cell vaccine "Cvac" for late-stage epithelial ovarian cancer. The company is in the development stage with no commercial products generating revenue. It operates clinical trials in Australia, Europe, and the United States. In June 2012, the company listed its American Depositary Shares (ADS) on the NASDAQ Global Market.
Key Financial Metrics (Fiscal Year Ended June 30, 2012)
| Metric | 2012 (A$) | 2011 (A$) |
|---|---|---|
| Total Revenue | 4,202,567 | 1,066,196 |
| Net Loss | (19,940,960) | (21,081,167) |
| Loss Per Share (Basic/Diluted) | (0.0192) | (0.0374) |
| Cash and Cash Equivalents | 16,991,716 | 45,918,552 |
| Held-to-Maturity Investments | 21,045,423 | 10,000,000 |
| Total Assets | 41,612,671 | 57,640,661 |
| Total Liabilities | 4,454,800 | 2,541,531 |
| Shareholders' Equity | 37,157,871 | 55,099,130 |
| Long-term Debt | Nil | Nil |
Note: All figures are in Australian Dollars (A$). Revenue consists primarily of interest income (A$2.7M) and government grant income (A$1.5M).
Material Changes vs. Prior Period
- Revenue Increase: Revenue increased 294% to A$4.2 million, driven by higher interest income due to increased cash holdings and A$1.5 million in R&D tax rebates.
- Net Loss Reduction: Net loss decreased by approximately A$1.1 million (5%) to A$19.9 million, despite higher operating expenses, due to the significant revenue increase.
- Expense Growth:
- R&D Expenses: Increased 52% to A$14.5 million due to the commencement of clinical trials in Australia, Europe, and the US.
- Administrative Expenses: Increased 39% to A$7.8 million due to headcount growth and international expansion.
- Finance Expenses: Decreased to zero from A$6.4 million in 2011 following the termination of the SpringTree convertible loan facility in March 2011.
- Derivative Losses: A new expense of A$1.5 million arose from changes in the fair value of forward exchange contracts.
- Liquidity Position: Cash and cash equivalents decreased by A$28.9 million to A$17.0 million, primarily due to operating cash outflows and investing activities (purchase of term deposits).
Guidance, Outlook, and Risks
Outlook and Capital Requirements: The company anticipates continuing to incur substantial losses as it advances the Cvac program. Management believes current cash and cash equivalents (A$17.0M) plus term deposits (A$21.0M) are sufficient to fund operations for more than 12 months. However, the company expects to require substantial additional funds to achieve long-term goals, complete clinical trials, and commercialize products. Future funding may be sought through public/private financings or licensing arrangements.
Key Risks and Contingencies:
- Development Risk: Success depends on the successful development and regulatory approval of Cvac. Clinical trials may fail to show sufficient safety or efficacy.
- Profitability: The company has a history of operating losses and an accumulated deficit of A$99.7 million. There is no guarantee it will ever achieve profitability.
- Regulatory Approval: Approval by the FDA, EMA, and other authorities is not guaranteed and is subject to extensive regulation.
- Manufacturing: Cvac is manufactured on a patient-by-patient basis, creating logistical challenges and reliance on third-party contractors.
- Intellectual Property: Risks include potential infringement of third-party patents (specifically Oncothyreon Inc. patents in the US) and the inability to secure necessary licenses.
- Internal Controls: The company identified a material weakness in internal controls over financial reporting in 2011 regarding the accounting of complex financial agreements. Management states this has been remediated in 2012 through hiring additional staff and implementing new review procedures.
Important Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the A$38 million in liquid assets (cash + term deposits) against the projected burn rate for the ongoing CANVAS Phase II/III trial.
- Revenue Composition: Confirm that revenue is non-operational (interest and grants) and that the company has no product sales.
- Internal Control Remediation: Assess the effectiveness of the new internal controls implemented to address the 2011 material weakness.
- Intellectual Property Status: Review the status of the Oncothyreon Inc. patent agreement and the potential impact on US commercialization prior to April 2018.
- Derivative Exposure: Monitor the impact of foreign exchange fluctuations on the company's financial results, given the A$1.5 million loss in 2012 from derivative fair value changes.